Medtronic Seals FDA Panel Endorsement With InFuse Bone Growth Product
This article was originally published in The Gray Sheet
Executive Summary
Preclinical studies of the effects of recombinant human bone morphogenetic protein-2 (rhBMP-2) on tumorogenicity, dosing and antibody response during pregnancy should be conducted by Medtronic/Sofamor Danek, FDA's Orthopedic & Rehabilitation Devices Panel recommended Jan. 10